Waligóra-Dziwak Katarzyna, Dańczak-Pazdrowska Aleksandra, Jenerowicz Dorota
Department of Dermatology, Poznan University of Medical Sciences, 60-355 Poznan, Poland.
Int J Mol Sci. 2025 Apr 29;26(9):4230. doi: 10.3390/ijms26094230.
While clinical trials have shown the efficacy of using dupilumab and upadacitinib to treat atopic dermatitis (AD), long-term real-world data remain limited. This retrospective cohort study, utilizing data from the Polish National Health Fund Registry, evaluates the long-term effectiveness of dupilumab versus upadacitinib in early treatment responders, focusing on sustained efficacy outcomes and high levels of skin clearance. Data from the Polish National Health Fund Registry were analyzed for 435 patients; 220 were treated with dupilumab and 215 were treated with upadacitinib, each receiving treatment for at least 40 weeks. Upadacitinib had a faster onset of action, leading to significantly higher rates of complete skin clearance compared to dupilumab at weeks 16 and 28 (EASI100 at week 16: 19.5% vs. 7.3%, < 0.001; week 28: 26.5% vs. 12.7%, < 0.001). Dupilumab showed continuous efficacy gains, ultimately demonstrating superiority in achieving EASI75 and EASI90 at week 40, though no significant difference was observed in achieving EASI100. Both treatments provided sustained dermatological improvement and enhanced quality of life, achieving high levels of skin clearance over the long term.
虽然临床试验已显示使用度普利尤单抗和乌帕替尼治疗特应性皮炎（AD）的疗效，但长期的真实世界数据仍然有限。这项回顾性队列研究利用波兰国家卫生基金登记处的数据，评估度普利尤单抗与乌帕替尼在早期治疗反应者中的长期有效性，重点关注持续疗效结果和高水平的皮肤清除率。对波兰国家卫生基金登记处的435名患者的数据进行了分析；220名患者接受度普利尤单抗治疗，215名患者接受乌帕替尼治疗，每人接受治疗至少40周。乌帕替尼起效更快，在第16周和第28周时，与度普利尤单抗相比，完全皮肤清除率显著更高（第16周时EASI100：19.5%对7.3%，<0.001；第28周时：26.5%对12.7%，<0.001）。度普利尤单抗显示出持续的疗效提升，最终在第40周实现EASI75和EASI90方面表现出优势，尽管在实现EASI100方面未观察到显著差异。两种治疗方法都提供了持续的皮肤改善并提高了生活质量，长期实现了高水平的皮肤清除率。
